Journal
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 15, Issue 11, Pages 1455-1464Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2009.07.017
Keywords
Autologous hematopoietic stem cell transplantation; Lymphoma; Rituximab
Categories
Funding
- National Cancer Institute (NICT) [U24-CA76518]
- National Heart, Lung and Blood Institute (NTHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- NHLBI [5U01HL069294]
- NCI
- Health Resources and Services Administration [HHSH234200637015C]
- Office of Naval Research [N0001406-1-0704, N00014-08-1-0058]
- AABB
- Aetna
- American Society for Blood and Marrow Transplantation
- Amgen, Inc
- Association of Medical Microbiology
- Infectious Disease Canada
- Astellas Pharma US, Inc
- Baxter International, Inc
- Bayer HealthCare Pharmaceuticals
- BloodCenter of Wisconsin
- Blue Cross and Blue Shield Association
- Bone Marrow Foundation
- Canadian Blood and Marrow Transplant Group
- Celgene Corp
- CellGenix GmbH
- Centers for Disease Control and Prevention
- ClinImmune Labs
- CTI Clinical Trial and Consulting Services
- Cubist Pharmaceuticals
- Cylex, Inc
- CytoTherm
- DOR BloPharma, Inc
- Dynal Biotech
- Invitrogen Company
- Enzon Pharmaceuticals, Inc
- European Group for Blood and Marrow Transplantation
- Gambro BCT, Inc
- Gamida Cell, Ltd
- Genzyme Corp
- Histogenetics, Inc
- HKS Medical Information Systems
- Hospira, Inc
- Infectious Diseases Society of America
- Kiadis Pharma
- Kirin Brewer, Co, Ltd
- Merck Company
- Medical College of Wisconsin
- MGI Pharma, Inc
- Michigan Community Blood Centers
- Millennium Pharmaceuticals, Inc
- Miller Pharmacal Group
- Millinian USA, Inc
- Miltenyi Biotec, Inc
- National Marrow Donor Program
- Nature Publishing Group
- New York.Blood Center
- Novartis Oncology
- Oncology, Nursing Society
- Osiris Therapeutics, Inc
- Otsuka Pharmaceutical Development & Commercialization, Inc
- Pall Life Sciences
- PDL BioPharma, Inc
- Pfizer Inc
- Pharmion Corp
- Saladax Biomedical, Inc
- Schering Plough Corp
- Society for Healthcare Epidemiology of America
- StemCyte, Inc
- StemSoft Soft-ware, Inc
- Sysmex
- Teva Pharmaceutical Industries
- Marrow Foundation
- THERAKOS, Inc
- Vidacare Corp
- Vion Pharmaceuticals, Inc
- VitaCorLaboratories
- ViroPharma, Inc
- Wellpoint, Inc
Ask authors/readers for more resources
Incorporation of the anti-CD20 monoclonal antibody rituximab into front-line regimens to treat diffuse large B cell lymphoma (DLBCL) has resulted in improved survival. Despite this progress, however, many patients develop refractory or recurrent DLBCL and then undergo autologous hematopoietic stem cell transplantation (AuHCT). It is unclear to what extent pre-transplant exposure to rituximab affects outcomes after AuHCT Outcomes of 994 patients receiving AuHCT for DLBCL between 1996 and 2003 were analyzed according to whether rituximab was (n = 176; +R cohort) or was not (n = 818; -R cohort) administered with front-line or salvage therapy before AuHCT The +R cohort had superior progression-free survival (PFS; 50% vs 38%; P = .008) and overall survival (OS; 57% vs 45%; P = .006) at 3 years. Platelet and neutrophil engraftment were not affected by exposure to rituximab. Nonrelapse mortality (NRM) did not differ significantly between the 2 cohorts. In multivariate analysis, the +R cohort had improved PFS (relative risk of relapse/progression or death, 0.64; P < .001) and improved OS (relative risk of death, 0.74; P = .039). We conclude that pre-transplant rituximab is associated with a lower rate of progression and improved survival after AuHCT for DLBCL, with no evidence of impaired engraftment or increased NRM. Biol Blood Marrow Transplant 15: 1455-1464 (2009) (C) 2009 American Society for Blood and Marrow Transplantation
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available